Results 81 to 90 of about 2,198,265 (159)

Echocardiographic red flags of ATTR cardiomyopathy a single centre validation

Aims: Echocardiography plays an important role in suspecting the presence of transthyretin cardiomyopathy (ATTR-CM) in patients with heart failure, based on parameters proposed as ‘red flags’ for the diagnosis of ATTR-CM.
Henein, Michael Y., Pilebro, Björn,, Lindqvist, Per,, Lindqvist, Per, Henein, Michael Y.,, Pilebro, Björn   +5 more
core   +1 more source

Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) has a specific pathophysiology, with myocardial stiffening and systolic dysfunction only in advanced stages. We aimed to investigate the response to cardiac resynchronization therapy (CRT) in ATTR‐
Alberto Aimo, Martina Nesti, Giuseppe Vergaro, Ammar M. Killu, Dimitrios Bampatsias, Daniela Tomasoni, Cinzia Forleo, Francesco Musca, Matteo Serenelli, Julie Rosenthal, Sergio L. Teruya, Nader J. Al‐Shakarchi, Mariel S. Tameze, Vincenzo Castiglione, Alessio Nicolai, Giorgia Panichella, Riccardo Saro, Aldostefano Porcari, Giulio Sinigiani, Vera Fico, Elisa Frau, Reem Matar, Andrea I. Guaricci, Giacomo Tini, Alberto Cipriani, Maria B. Musumeci, Simone Longhi, Cristina Chimenti, Marco Metra, Martha Grogan, Federico Perfetto, Francesco Cappelli, Marco Merlo, Gianfranco Sinagra, Mathew S. Maurer, Ahmad Masri, Michele Emdin   +36 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Final International Classification of diseases (ICD-10) code list for identifying potential ATTR-CM cases in DATASUS.

Final International Classification of diseases (ICD-10) code list for identifying potential ATTR-CM cases in DATASUS.
Fabio Fernandes (3386423), Isabella Zuppo Laper (17972784), Marcus Vinicius Simões (5224412), Claudenice Leite Bertoli de Souza (17972790), Ariane de Jesus Lopes de Abreu (14425084), Rafaela Vansan Ferreira (14425090), Edileide de Barros Correia (17972793), Guilherme Silva Julian (8520117), Cecilia Camacho-Hubner (17972787)   +8 more
core   +1 more source

Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACT

Cardiology and Therapy
Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of results of the phase 3 study ATTR-ACT. This post hoc analysis from ATTR-ACT evaluated the effect of tafamidis on transthyretin (TTR) concentration ...
Mathew S. Maurer, Perry Elliott, Jeffery W. Kelly, Mazen Hanna, Evan T. Powers, Steve Riley, Rong Wang, Pablo Garcia-Pavia   +7 more
doaj   +1 more source

Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE‐CM, a Randomized Controlled Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) carries high risk for all‐cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular hospitalization (CVH). NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) and serum TTR (sTTR)
Onyedika John Ilonze, Daniel Philip Judge, Ahmad Masri, Prem Soman, Francesco Cappelli, Michel Georges Khouri, Nitasha Sarswat, Mazen Hanna, Yuxi Liu, Gillian Murtagh, Kuangnan Xiong, Adam Castaño, Jean‐François Tamby, Jonathan C. Fox, Uma Sinha, Jan Marie Griffin, Julian D. Gillmore, James Louis Januzzi   +17 more
doaj   +1 more source

Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a rare, life‐threatening form of restrictive cardiomyopathy. Access to cardiology providers and specialized amyloid centers may impact ATTR‐CM diagnosis.
Joshua D. Mitchell, Kevin M. Alexander, Hanh Dung Dao, Elizabeth Nagelhout, Neil Lamarre, Margarita Udall, Richard K. Cheng   +6 more
doaj   +1 more source

Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review

Introduction Significant advances in the treatment of transthyretin (ATTR) amyloidosis has led to an evolving understanding of the epidemiology of this condition. This systematic literature review (SLR) aims to synthesize current evidence on epidemiology
Firas Dabbous, Divya Shridharmurthy, Faizan Mazhar, Nitin Shivappa, Krister Järbrink, Eric Wittbrodt, Diego Delgado   +6 more
core   +1 more source

Erythropoietin in Familial Amyloidosis ATTR V30M

, 2013
Familial amyloidosis ATTR V30M is an hereditary disorder, the most frequent type of transthyretin related amyloidosis. The main manifestation of the disease is a sensory-motor and autonomic polyneuropathy.
Costa, P.P., Beirão, I.
core   +1 more source

Determinants and Monitoring of Response to Disease-Modifying Therapy for Transthyretin Amyloidosis Cardiomyopathy: The ATTR-CM Therapy Study

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a heart muscle disease characterized by the accumulation of misfolded transthyretin proteins as amyloid plaques in the myocardial interstitium.
Shahi, Karan
core   +1 more source